VT
ALNY icon

Vise Technologies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Vise Technologies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$602K Hold
1,515
– – 0.01% 785
2025
Q4 		$602K Buy
1,515
+491
+48% +$217K 0.01% 790
2025
Q3 		$467K Sell
1,024
-310
-23% -$126K 0.02% 694
2025
Q2 		$435K Buy
+1,334
New +$369K 0.02% 697

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vise Technologies's ALNY Position: Q1 2026 in Review

Vise Technologies held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 1,515 shares worth $602K. The position accounts for 0.01% of the portfolio, ranked #785.

Vise Technologies first reported a position in ALNY in Q2 2025 and has held it in 4 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Vise Technologies held 1,515 shares of Alnylam Pharmaceuticals worth $602K as of Q1 2026.
  • Vise Technologies left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
  • Alnylam Pharmaceuticals made up 0.01% of Vise Technologies's portfolio in Q1 2026, its #785 holding.
  • Vise Technologies first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Vise Technologies's 13F filing for Q1 2026, filed 21 Apr 2026.